.jpeg)
2026-07-14 05:26:41
Lorlatinib is an oral tyrosine kinase inhibitor indicated for ALK-positive advanced non-small cell lung cancer (NSCLC). The recommended dose is 100 mg once daily. Treatment must be initiated by a physician experienced in anticancer therapy and preceded by ALK genetic testing. This article covers dosing, mechanism of action, common side effects, and key contraindications.
2026-07-13 07:43:38
On June 24, 2026, the FDA approved Pfizer’s Ibrance (palbociclib) in combination with anti-HER2 therapy and endocrine therapy for maintenance treatment of HR+/HER2+ advanced breast cancer, based on Phase III PATINA trial results.
2026-07-13 07:34:24
The U.S. FDA approved Gilead’s Trodelvy (sacituzumab govitecan) on June 24, 2026, for first-line treatment of advanced triple-negative breast cancer (TNBC), based on Phase III ASCENT-03 and ASCENT-04 data.
2026-07-10 06:43:53
An in-depth analysis of Cabozantinib's multi-kinase inhibition mechanism and its established role in treating renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer globally.
2026-07-10 06:37:28
This article provides a comprehensive overview of infusion-related reactions (IRRs) associated with Amivantamab. It covers preventive premedication, step-up dosing strategies, and protocols for managing adverse events in clinical settings.
2026-06-23 06:15:37
This article reviews clinical response patterns of margetuximab combined with chemotherapy for HER2-positive metastatic breast cancer, based on the Phase 3 SOPHIA trial. It details median time to response, RECIST evaluation cycles, key efficacy data, and factors influencing therapeutic outcomes.
2026-06-16 04:31:29
This article presents the eligible population, mechanism of action and clinical positioning of the avutometinib + defactinib combination regimen, and elaborates its clinical value and prerequisite for use in precision treatment of low-grade serous ovarian cancer.
2026-06-12 02:43:12
This article provides a comprehensive overview of vemurafenib (brand name Zelboraf), a targeted therapy for BRAF V600 mutation-positive melanoma. It covers standard dosage, administration instructions, dose adjustment principles, special population considerations, treatment monitoring requirements, and important safety information for patients and healthcare professionals.
2026-06-08 03:30:02
A comprehensive guide to the safety of Durvalumab (Imfinzi), detailing the identification, grading, and management of immune-related adverse events across multiple organ systems.
2026-06-08 03:18:47
Based on pivotal SPOTLIGHT and GLOW Phase III trials, this article analyzes the efficacy, durability of response, and real-world feedback of Zolbetuximab for advanced gastric cancer.
2026-06-08 03:13:03
A comprehensive guide to Mitotane resistance in ACC, covering its definition, mechanisms, and subsequent strategies including chemotherapy, targeted therapy, and clinical trial participation for patients and caregivers.
2026-06-08 02:54:25
Discover the latest 2026 data on Trametinib (Mekinist) plus Dabrafenib for BRAF V600-mutant tumors. This article covers efficacy, global cost insights, dosing, and side effect management for patients and caregivers worldwide.
